Discover
AlphaNooner by AdvisorShares
166 Episodes
Reverse
What is Ross Gerber watching heading into 2027? The president and CEO of @Gerberkawasaki joins Mackenzie Peterson on AdvisorShares' AlphaNooner to talk AI stocks after Nvidia's earnings, why he'd wait until after Anthropic's IPO to buy shares, and why his firm invested in Take-Two Interactive ahead of Grand Theft Auto VI.- Nvidia NVDA and Apple AAPL. Where Gerber sees opportunity as AI moves from building infrastructure to everyday use. - Anthropic IPO. How he thinks about the valuation, why he'd wait to buy shares, and how his firm uses Claude for financial planning. - GTA 6 and Take-Two Interactive TTWO. What the launch could mean for Take-Two and where Gerber sees an opportunity for recurring revenue. - Eli Lilly LLY and GLP-1s. Why Gerber is watching how Lilly reinvests profits from its weight-loss drugs. - 2027 stock market outlook. What lower inflation and interest rates could mean for consumer discretionary stocks.Subscribe on YouTube → https://www.youtube.com/@AdvisorShares?sub_confirmation=1 Listen on Apple Podcasts or Spotify → https://advisorshares-alphanooner.transistor.fm/subscribeAlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio managers and industry experts on markets, investment themes and the stories shaping what comes next.Watch the full video on YouTube: https://www.youtube.com/watch?v=EHqKMjJZd8kFollow AdvisorShares (@advisorshares) on YouTube, X, LinkedIn, Instagram and Facebook.
What's next for Rubicon Organics and Canada's premium cannabis market?Margaret Brody, CEO of Rubicon Organics, joins AdvisorShares AlphaNooner to discuss the company's Q3 2026 earnings, production expansion, and evolving demand for premium cannabis products.With year-to-date net revenue up 17%, Rubicon is focused on scaling cultivation, improving production efficiency, and strengthening its position in Canada's competitive cannabis industry.In this conversation, we cover:Q3 2026 earnings: Revenue growth, adjusted EBITDA, and key financial takeaways.Production expansion: Cultivation capacity, yields, and the challenges of scaling premium cannabis.Canadian cannabis market: Consumer demand, pricing pressures, and competition from the illicit market.International opportunities: Export markets and the evolving global cannabis industry.Cannabis consumer trends: Premium flower, pre-rolls, vapes, and changing product preferences.2026 outlook: What investors should watch as Rubicon continues expanding.Subscribe to AlphaNooner for conversations with company executives, portfolio managers, and industry leaders covering cannabis, psychedelics, financial markets, and emerging investment trends.Watch AlphaNooner Tuesdays and Thursdays at 12 p.m. ET on YouTube, X, and LinkedIn, or listen wherever you get your podcasts.#RubiconOrganics #CannabisIndustry #CannabisInvesting #AlphaNoonerAlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio managers and industry experts on markets, investment themes and the stories shaping what comes next.Watch the full video on YouTube: https://www.youtube.com/watch?v=49WV1mnBoxoFollow AdvisorShares (@advisorshares) on YouTube, X, LinkedIn, Instagram and Facebook.
Federal cannabis rescheduling remains on track, but investors are still waiting for the next official update. What could come next for cannabis stocks, and which developments could shape the industry heading into 2027?On this episode of AlphaNooner, AdvisorShares' Dan Ahrens joins Mackenzie Peterson to discuss the outlook for cannabis reform, the latest developments at Trulieve and Glass House Brands, changes to hemp regulation, and growing momentum in psychedelic medicine.From federal policy to company-specific catalysts and FDA developments, Dan breaks down what matters for investors and what he's watching through year-end.AlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio managers and industry experts on markets, investment themes and the stories shaping what comes next.Watch the full video on YouTube: https://www.youtube.com/watch?v=fWo2KSU9KtQFollow AdvisorShares (@advisorshares) on YouTube, X, LinkedIn, Instagram and Facebook.
What leads someone to consider psychedelic medicine, and what changes their mind about it?Navy veteran Graham Ginn joins AlphaNooner to share how childhood trauma, a mental health crisis, and a later cancer diagnosis shaped his journey from skepticism to psychedelic advocacy.Ahead of Veterans Day, the conversation explores how veterans are helping change public perceptions of psychedelics, while highlighting the many reasons people seek help across military and civilian life.In this episode:• Graham's story: Confronting childhood trauma and patterns of self-sabotage that followed him into adulthood. • A change in perspective: How he describes the impact of psychedelic experiences on his relationships, sense of purpose, and fear of death. • Preparation and integration: Why the work surrounding a psychedelic experience matters. • Challenging stigma: How veterans' experiences are opening conversations about mental health and treatment options. • Expanding access: Graham's views on research, advocacy, and the proposed Freedom to Heal Act.This conversation reflects personal experiences and opinions. It is for educational purposes and is not medical advice.AlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio managers and industry experts on markets, investment themes and the stories shaping what comes next.Watch the full video on YouTube: https://www.youtube.com/watch?v=2fSI2WvJ_HQFollow AdvisorShares (@advisorshares) on YouTube, X, LinkedIn, Instagram and Facebook.
Is the AI bubble starting to burst? As investors question soaring tech valuations, massive AI infrastructure spending, and the debt financing the boom, Chris Irons of QTR's Fringe Finance joins AlphaNooner to discuss the risks building beneath the stock market rally.From CoreWeave and the AI trade to Federal Reserve policy, credit markets, and the potential for a broader market correction, Chris explains where he sees warning signs and how investors might navigate a changing market.The AI bubble: Are valuations and infrastructure spending getting ahead of the underlying economics?Debt and credit markets: What rising borrowing costs and credit spreads could signal about the AI investment boom.CoreWeave and speculative tech stocks: Chris's concerns about valuations, leverage, and investor expectations.The Federal Reserve: Have years of central bank intervention changed how investors think about risk?The next market correction: How deleveraging could spread from speculative assets to the broader economy.Dow vs. Nasdaq: Why Chris is looking more closely at established, cash-generating businesses.Chris Irons is the founder of QTR's Fringe Finance, where he writes about financial markets, investing, and economic trends.AlphaNooner by AdvisorShares brings you timely conversations with investors, market strategists, portfolio managers and industry experts on markets, investment themes and the stories shaping what comes next.Watch the full video on YouTube: https://www.youtube.com/watch?v=EXqFd4OIjQkFollow AdvisorShares (@advisorshares) on YouTube, X, LinkedIn, Instagram and Facebook.



